Evidence map›Paper›PMID 41286496›Full record

ArticleNPJ precision oncology2025

CanRisk-DB: an artificial intelligence-driven comprehensive database of cancer risk factors.

Yongjie Xu, Changfa Xia, Shiyuan Tong, Hui Yu, Fang Liu, Shiqing Chen, Jing Liu, Yujie Wu, Jiachen Wang, Qianru Li and 2 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yongjie Xu *Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Changfa Xia *Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shiyuan Tong *Shanghai Xiaohe Medical Laboratory Co., Ltd., Shanghai, China.
Hui YuShanghai Xiaohe Medical Laboratory Co., Ltd., Shanghai, China.
Fang LiuShanghai Xiaohe Medical Laboratory Co., Ltd., Shanghai, China.
Shiqing ChenShanghai Xiaohe Medical Laboratory Co., Ltd., Shanghai, China.
Jing LiuShanghai Xiaohe Medical Laboratory Co., Ltd., Shanghai, China.
Yujie WuOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jiachen WangOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qianru LiOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sibo ZhuShanghai Xiaohe Medical Laboratory Co., Ltd., Shanghai, China. zhusibo.1@bytedance.com.
Wanqing ChenOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. chenwq@cicams.ac.cn.

Funding

Ministry of Science and Technology of the People's Republic of China 2024ZD0520000Ministry of Science and Technology of the People's Republic of China 2024ZD0520003National High Level Hospital Clinical Research Funding and Cooperation Fund of CHCAMS and SZCH CFA202202004National Natural Science Foundation of China 82273721National Natural Science Foundation of China 82303609
6 · The paper itself

Abstract

Cancer development is influenced by a complex interplay of diverse risk factors, but synthesizing this fragmented research remains challenging. To address this, we developed CanRisk-DB, an Artificial intelligence (AI)-driven database that systematically aggregates and standardizes published evidence on cancer-associated risk factors. Using a multi-stage AI pipeline based on the PICOS framework, we analyzed 435,975 publications from PubMed, Embase, and Cochrane (2000-2024), employing a Graph-based Retrieval-Augmented Generation framework to extract cancer types, risk factors, and quantitative estimates (e.g., relative risk [RR], hazard ratio [HR], standardized incidence ratio [SIR]). In the literature screening stage, the system demonstrated high accuracy and efficiency. From 9550 relevant articles, CanRisk-DB compiled 445,646 standardized records covering 76 risk factor groups and 42 cancer types across 80 countries over 50 years. Validated against benchmark datasets, this publicly accessible resource constitutes a comprehensive knowledge base of cancer risk factors, supporting etiological research, risk analyses, and the development of evidence-informed prevention strategies. The CanRisk-DB is available at http://www.canrisk-ai.com .

Identifiers

PMID41286496
PMCPMC12644518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.